ReviewEuropean journal of epidemiology2019
Measles, the need for a paradigm shift.
Review in European journal of epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Onward Virus Transmission after Measles Secondary Vaccination Failure.Emerging infectious diseases · 2024Pooled it
- A commentary on measles vaccine in the context of outbreaks: Viral evolution, waning immunity and public trust.Human vaccines & immunotherapeutics · 2025Review
- Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity.NPJ vaccines · 2025Article
- Genetic characterization of measles virus circulating in Iran, 2021-2023.BMC infectious diseases · 2025Article
- Concordance of coverage estimates from routine and survey data of measles second dose vaccine in Western Kenya.Frontiers in epidemiology · 2025Article
- Breakthrough Measles among Vaccinated Adults Born during the Post-Soviet Transition Period in Mongolia.Vaccines · 2024Article
- Prevalence and management of rubella susceptibility in healthcare workers in Italy: A systematic review and meta-analysis.Vaccine: X · 2022Article
- Low Measles Seropositivity Rate among Thai Adolescents in the Thai National Immunization Program.Vaccines · 2022Article
- Breakthrough Infections: A Challenge towards Measles Elimination?Microorganisms · 2022Review
- Characterization of Vaccine Breakthrough Cases during Measles Outbreaks in Milan and Surrounding Areas, Italy, 2017-2021.Viruses · 2022Article
- Prevalence of measles antibodies among migrant workers in Singapore: a serological study to identify susceptible population subgroups.BMC infectious diseases · 2022Article
- Molecular Epidemiology of B3 and D8 Measles Viruses through Hemagglutinin Phylogenetic History.International journal of molecular sciences · 2020Article
- Measles vaccine immune escape: Should we be concerned?European journal of epidemiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measles vaccination schedules and targets of herd immunity have been designed according to the paradigm that the vaccine is as protective as natural infection, and the virus has remained of a single serotype over many decades. As a result, ongoing measles resurgence is mostly attributed to gaps in immunization. Using official data, we investigated the correlation between the rate of vaccine coverage reported and aggregated at the national level, and the incidence of cases. We discussed the limits of this indicator considered in isolation. We provide a literature overview of measles vaccine efficacy and failures. We questioned whether measles strains could escape the vaccine. Immunization tools and strategies for measles control deserve to be optimized in the current context.
Indexed as
Identifiers
31624970What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.